The night of november 24thEast sunshine section(600673) publicity updateReorganization of acquisitionsReport, company acquisition port unitEast sunshine(01558. Hk) significant progress has been made on the issue of shares. The reorganization report indicates that the listed company intends to purchase its share of 226. 2 million shares (50. 04 per cent of its total equity) of east sunshine medicine at a total cost of rmb 3,221 million from the yichang sun medicines industry. When the deal is completed, the east sunshine will be listed as a holding subsidiary, and the east sunshine industry will extend toPharmaceutical industryArea. The company stock will be repeated on november 27th。
Injecting quality medical assets
Upon completion of the transaction, the east sunshine section will hold 50. 04 per cent of the shares of the east sunshine medicine and will have a stake in the latter. The original main operation of the east sunshine section, which is dominated by aluminum deep processing, chemical production, electronic materials and metaware manufacturing, will facilitate the expansion of the east sunshine industry to the pharmaceutical industry and achieve significant resultsIndustrial transformationI don't know. The east sunshine section is the same asset as the east sunshine medicine, and the acquisition will not result in a change of the listed company's control。
According to the data, the purchase of east sunshine, established in 2001 as a pharmaceutical enterprise with antiviral drugs at its core, covering the development, production and sale of drugs for the treatment of diseases such as antivirus, endocrine and cardiovascular diseases, was successfully listed on the main board of hong kong joint exchange in 2015。
In recent years, the scale and profitability of the operation of the east sunshine medicine has continued to increase. In 2016, the east sun medicines achieved an operating income of approximately 942 million yuan, an increase of 35. 65 per cent over 2015 and a net profit of about 381 million yuan, an increase of 43. 22 per cent over the same period. In january-june 2017, the east sunshine drug generated some $662 million in operating income and a net profit of some $295 million. Since 2017, the east sunshine has performed well in the hong kong stock market, with high stock prices, rising by more than 60 per cent since the beginning of the year and now worth more than hk$10 billion。
The yi changdong sun medicines industry committed itself in the profit forecast compensation agreement to a net profit of not less than 577 million yuan in 2018, 653 million yuan in 2019 and 689 million yuan in 2020。
In its reorganization report, the east sunshine section stated that the reorganization would facilitate the entry of companies into the pharmaceutical industry, which had great prospects for development, and the continuous upgrading of the company's innovative development capacity through capital markets both within and outside the country。
The chinese version of "gidley"
It is known that the main hit product of the east sunshine medicine is currently “canway”. The active active ingredient in vi is othavi phosphate, whose effectiveness against different strains of influenza has been widely recognized worldwide and is included as a “basic drug” in the world health organization's model drug catalogue。
At the national level, it is the dominant product in the market for phosphate products, and in 2009 and 2017 it was incorporated into the national health insurance catalogue. As a result of the “capable” efforts, the performance of east sunshine has remained high, with a combined growth rate of about 36. 8 per cent in operating income in 2012-2016, and a combined increase in net profits of up to 101. 7 per cent, with the products now in the top four markets for our anti-influenza products. Taking into account the vast scope of the influenza drug market and the exceptionally high market share of eastern sunshine, “canta” will continue to grow strongly in the future and become a heavy-pound species that have long maintained high levels of profitability。
The combi found that the development of east sunshine is quite similar to that of the top drug company, gidley. Founded in 1987 in silicon valley, it is the only emerging company in the world with a market value of over a hundred billion dollars that has been in existence for only 30 years, with a drug called sovaldi, in the area of hepatitis c, known as “the most lucrative potion in history”, and thus also known as “the king of hepatitis c”。
In addition to the core product, the east sunshine medicine, which has a hepatitis c dose in research products, is currently undergoing a clinical combination study, with the goal of introducing the full oral defusing agent hepatitis c combination by the end of 2020. This drug, called "imitave phosphate", is the country's most advanced 1. 1 new drug for the anti-hepatitis c virus and was approved as early as december of last year by the office of drug control and drug administration for the ii/iii clinical trial。
At the same time, the east sunshine drug has been working with the taipei medicine of taiwan's listed company to combine the phosphorus acid with the latter's furaprevir, and plans to develop a new full oral free-of-disturbing prop hepatitis combination therapy。
It is known that, in addition to “canway” and imitate phosphate, there is also a wealth of future product reserves for east sunshine. The report revealed that, as at 30 june 2017, the company owned 18 major products at different stages of development, covering treatment areas such as endocrine and metabolic disease products, digestive disease products and antiviral products。
Large shareholders are showing confidence in transition
On the same day, the eastern sunshine holding shareholders, deep east, issued a plan announcement that, within six months of the rebranding of the card, deep east would add together no more than 4,937. 5 million shares, not more than 2 per cent of the company's current total share. Previously, on 10 october 2017, the east sunshine section had announced that the controlling shareholders would hold 1. 9318 million shares (0. 686 per cent of the company's total equity) in all corporate shares held under the employee-held scheme of the company. This additional increase demonstrates the confidence of large shareholders in the future transformation of the company。
